Inhibiting 2-AG breakdown with MJN110 dose-dependently reduced post-traumatic headache in concussed mice by attenuating CGRP expression and glial activation in the trigeminal pain pathway.
Dose-dependent pain reliefMJN110 reduced post-traumatic headache in proportion to dose by attenuating CGRP expression in the trigeminal pain pathway after repetitive mild TBI
What the researchers found
MJN110 (MAGL inhibitor) dose-dependently attenuated post-traumatic headache in mice after repetitive mild TBI by reducing CGRP expression and glial activation in the trigeminal ganglion and nucleus caudalis, with effects mediated through cannabinoid receptor activation.
Why it matters
Post-concussion headaches affect millions of people and current treatments are often inadequate. This study identifies a new therapeutic approach — boosting endocannabinoids to reduce CGRP-mediated pain — that could complement or provide an alternative to existing CGRP-targeting migraine drugs for post-traumatic headache.
The numbers in context
Male C57BL/6J mice with repetitive mild TBI treated with MAGL inhibitor to boost endogenous 2-AG levels.
How the study worked
Repetitive mild TBI was induced in male C57BL/6J mice using the CHIMERA model. Periorbital allodynia was measured with von Frey filaments. CGRP expression and glial activation were assessed by immunofluorescence in the trigeminal ganglion and nucleus caudalis. Endocannabinoid levels (2-AG, AEA, AA) were measured by mass spectrometry. MJN110 effects were tested with cannabinoid receptor antagonists and the 2-AG synthesis inhibitor DO34.
Who was studied
Male C57BL/6J mice with repetitive mild TBI
What this study cannot tell us
Mouse model of TBI — human post-concussion headaches are more complex. Only male mice were used, despite known sex differences in both migraine and TBI outcomes. MJN110 is a research tool compound, not an approved drug. The CHIMERA model may not fully replicate the spectrum of human concussions. Long-term effects were not assessed.
How to read the evidence
Preliminary evidence from a well-designed animal study with multiple mechanistic validations (dose-response, antagonist blocking, synthesis inhibition). Translation to human post-concussion headache treatment remains to be tested.
When this study was published
Published in 2024, reflecting growing interest in endocannabinoid-based approaches for neurological conditions and the intersection with CGRP pain pathways.
The bigger picture
Post-traumatic headache sits at the intersection of two major research areas: endocannabinoid medicine and CGRP-targeted migraine therapy. This study shows these pathways are linked — endocannabinoid boosting reduces CGRP, suggesting that future treatments could leverage this connection. It also adds to growing evidence that the endocannabinoid system is disrupted after brain injury and that restoring it could be therapeutic.
Questions still open
- Would MAGL inhibitors be effective for post-traumatic headache in humans, and could they be combined with CGRP-blocking drugs?
- Are endocannabinoid levels disrupted in human concussion patients with persistent post-traumatic headache?
- Do female mice show the same response to endocannabinoid modulation for post-TBI headache?
Common questions
What does the endocannabinoid system have to do with headaches?
Could this lead to new treatments for persistent headaches after concussion?
Read the original research
Inhibition of 2-AG hydrolysis alleviates posttraumatic headache attributed to mild traumatic brain injury.
The journal of headache and pain, 25(1), 115
Citation
Wen, Jie; Tanaka, Mikiei; Zhang, Yumin. (2024). Inhibition of 2-AG hydrolysis alleviates posttraumatic headache attributed to mild traumatic brain injury.. The journal of headache and pain, 25(1), 115. https://doi.org/10.1186/s10194-024-01817-z